CoChat

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Open access
Basheer, Neha, Smolek, Tomáš, Hassan, Imtaiyaz, Liu, Fei, Iqbal, Khalid, Zilka, Norbert, Novak, Petr · 2023 · Molecular Psychiatry

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

Abstract

Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets in current pharmacological research, with indications ranging from oncology to neurodegeneration. Tau protein hyperphosphorylation was the first pathological post-translational modification of tau protein described in Alzheimer’s disease (AD), highlighting the role of PKs in neurodegeneration. The therapeutic potential of protein kinase inhibitors (PKIs)) and protein phosphatase 2 A (PP2A) activators in AD has recently been explored in several preclinical and clinical studies with variable outcomes. Where a number of preclinical studies demonstrate a visible reduction in the levels of phospho-tau in transgenic tauopathy models, no reduction in neurofibrillary lesions is observed. Amongst the few PKIs and PP2A activators that progressed to clinical trials, most failed on the efficacy front, with only a few still unconfirmed and potential positive trends. This suggests that robust preclinical and clinical data is needed to unequivocally evaluate their efficacy. To this end, we take a systematic look at the results of preclinical and clinical studies of PKIs and PP2A activators, and the evidence they provide regarding the utility of this approach to evaluate the potential of targeting tau hyperphosphorylation as a disease modifying therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-023-02113-z

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic showing 2N4R tau (441 amino acids), the longest isoform expressed encompassing major structural domains. The phosphosites identified for AD pathology (in red), physiology (in green) and overlapping sites for both physiology and pathology (in purple) are shown here. Therapeutically targeted protein kinases (PKs) and protein phosphatase (PPs) are colour coded to their respective inhibitors or modulators explored clinically or preclinically.
Fig. 1 Schematic showing 2N4R tau (441 amino acids), the longest isoform expressed encompassing major structural domains. The phosphosites identified for AD pathology (in red), physiology (in green) and overlapping sites for both physiology and pathology (in purple) are shown here. Therapeutically targeted protein kinases (PKs) and protein phosphatase (PPs) are colour coded to their respective inhibitors or modulators explored clinically or preclinically.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 222 references

Research works printed but not linked: 1

  1. Serenó L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sánchez MB, Gich I, et al. A novel GSK-3β inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009;35:359–67. · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P.
Affiliations
Slovak Academy of Sciences (SK)
Venue
Molecular Psychiatry
Published
2023-06
Volume
28
Issue
6
Pages
2197-2214
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4379093931
Cited by
159
References
222
Citations by year
2026: 57 · 2025: 56 · 2024: 43 · 2023: 3
FWCI
5.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky
  • Agentúra na Podporu Výskumu a Vývoja (APVV-20-0447, APVV-20-)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
tau hyperphosphorylation, Alzheimer's disease, protein kinase inhibitors, PP2A activators, protein kinases, disease-modifying therapy, neurofibrillary tangles, clinical trial results, preclinical drug testing
MeSH terms
Alzheimer Disease, Humans, Phosphorylation, Protein Kinases, tau Proteins, Tauopathies, Protein Phosphatase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. https://app.cochat.ai/papers/10.1038/s41380-023-02113-z
The paper
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023). Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02113-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.